The news followed an investigation by POLITICO's E&E News into climate-friendly inhalers and how drug giants are developing ...

Pharmaceutical giant GlaxoSmithKline is sidestepping its pledge to lower asthma inhaler prices, a key senator charged Wednesday, in the latest effort by Democrats to pressure drug companies on the ...

GSK has developed a new propellant technology for inhaler devices that drastically reduces their use of greenhouse gases, which perhaps surprisingly account for nearly half (49%) of the group’s ...

Flovent, a popular corticosteroid inhaler used to treat asthma, is no longer available. The global manufacturer, Glaxo Smith Kline (GSK), announced in May that the medications — Flovent HFA ...

GlaxoSmithKline is recalling more than 593,000 asthma inhalers in the US due to a defect that may cause them to deliver fewer doses of the medicine than indicated. The company said it would be ...

Massachusetts families are still struggling to find alternatives almost a year after GlaxoSmithKline canceled a widely ...

Americans with asthma and 16 million Americans with COPD need inhalers to breathe. Vermont Business Magazine Sen. Bernie Sanders (I-Vermont), Chairman of the Senate Com ...

Efforts to supplant pressurised metered-dose inhalers (pMDIs) with DPIs, most recently by the European Network on Climate and Health Education (ENCHE), have gained steam in recent years. Companies ...

Companies like AstraZeneca and GSK, which have high-revenue-generating inhalers for asthma and chronic obstructive pulmonary disorder (COPD) in their portfolios, have each committed to becoming ...

Nov 19 (Reuters) - British drugmaker GSK (GSK.L), opens new tab said on Tuesday its experimental therapy, linerixibat, met its main goal in a late-stage trial to treat patients with a so-called ...

GSK’sGSK2.90%increase; green up pointing triangle blood-cancer drug Blenrep showed positive overall survival data in a late-stage trial, increasing the likelihood for the treatment to return to ...